Eoin McKinney

Fergus Imrie, Bogdan Cebere, Eoin F. McKinney et al.

Diagnostic and prognostic models are increasingly important in medicine and inform many clinical decisions. Recently, machine learning approaches have shown improvement over conventional modeling techniques by better capturing complex interactions between patient covariates in a data-driven manner. However, the use of machine learning introduces a number of technical and practical challenges that have thus far restricted widespread adoption of such techniques in clinical settings. To address these challenges and empower healthcare professionals, we present a machine learning framework, AutoPrognosis 2.0, to develop diagnostic and prognostic models. AutoPrognosis leverages state-of-the-art advances in automated machine learning to develop optimized machine learning pipelines, incorporates model explainability tools, and enables deployment of clinical demonstrators, without requiring significant technical expertise. Our framework eliminates the major technical obstacles to predictive modeling with machine learning that currently impede clinical adoption. To demonstrate AutoPrognosis 2.0, we provide an illustrative application where we construct a prognostic risk score for diabetes using the UK Biobank, a prospective study of 502,467 individuals. The models produced by our automated framework achieve greater discrimination for diabetes than expert clinical risk scores. Our risk score has been implemented as a web-based decision support tool and can be publicly accessed by patients and clinicians worldwide. In addition, AutoPrognosis 2.0 is provided as an open-source python package. By open-sourcing our framework as a tool for the community, clinicians and other medical practitioners will be able to readily develop new risk scores, personalized diagnostics, and prognostics using modern machine learning techniques.

Mihaela van der Schaar, Richard Peck, Eoin McKinney et al.

This manifesto represents a collaborative vision forged by leaders in pharmaceuticals, consulting firms, clinical research, and AI. It outlines a roadmap for two AI technologies - causal inference and digital twins - to transform clinical trials, delivering faster, safer, and more personalized outcomes for patients. By focusing on actionable integration within existing regulatory frameworks, we propose a way forward to revolutionize clinical research and redefine the gold standard for clinical trials using AI.

Jeroen Berrevoets, Alicia Curth, Ioana Bica et al.

Choosing the best treatment-plan for each individual patient requires accurate forecasts of their outcome trajectories as a function of the treatment, over time. While large observational data sets constitute rich sources of information to learn from, they also contain biases as treatments are rarely assigned randomly in practice. To provide accurate and unbiased forecasts, we introduce the Disentangled Counterfactual Recurrent Network (DCRN), a novel sequence-to-sequence architecture that estimates treatment outcomes over time by learning representations of patient histories that are disentangled into three separate latent factors: a treatment factor, influencing only treatment selection; an outcome factor, influencing only the outcome; and a confounding factor, influencing both. With an architecture that is completely inspired by the causal structure of treatment influence over time, we advance forecast accuracy and disease understanding, as our architecture allows for practitioners to infer which patient features influence which part in a patient's trajectory, contrasting other approaches in this domain. We demonstrate that DCRN outperforms current state-of-the-art methods in forecasting treatment responses, on both real and simulated data.